Physician profile
Katie E Kunamneni
NPI 1164620001
$3,551.57
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $928 · 2021: $999 · 2022: $289 · 2023: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $603.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $475.10 | 2019-2021 | |
| Novo Nordisk INC | $300.24 | 2019-2022 | |
| Amarin Pharma, INC. | $253.63 | 2019-2021 | |
| Abbvie INC. | $207.63 | 2019-2022 | |
| Pfizer INC. | $182.70 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.03 | 2019-2020 | |
| Glaxosmithkline, LLC. | $171.54 | 2020-2022 | |
| Lilly USA, LLC | $154.69 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $149.87 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $149.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.70 | 2019-2022 | |
| Abbott Laboratories | $85.77 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.91 | 2019-2021 | |
| Ibsa Pharma INC. | $52.39 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.03 | 2021 | |
| Genentech USA, INC. | $39.57 | 2020-2021 | |
| Eisai INC. | $38.39 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.69 | 2019-2020 | |
| Horizon Therapeutics Plc | $29.23 | 2021-2023 | Krystexxa |
| Amgen INC. | $29.10 | 2019-2020 | |
| Allergan, INC. | $25.83 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $25.71 | 2020 | |
| Endo Pharmaceuticals INC. | $25.37 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.04 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $14.50 | 2021 | |
| Sanofi Pasteur INC. | $14.18 | 2019 | |
| Philips North America LLC | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Kunamneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.